Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC
Immunomedics has halted its Phase 3 confirmatory trial of sacituzumab govitecan, due to strong evidence of its ability to delay disease progression in patients with advanced triple-negative breast cancer (TNBC). Members of an independent data safety monitoring committee unanimously decided on an early stop to the ASCENT trial (NCT02574455), which was originally slated to end in July. “The remarkable results we observed across multiple endpoints in the ASCENT study warranted early discontinuation of the trial and are indicative of a potential major advance in the treatment of this devastating disease that affects younger women and African American women at higher rates,” Julie R. Gralow, MD, chairperson of the monitoring committee, said in a press release. “I look forward to the release of the full and final analyses of these study data when they are available for public presentation,” added Gralow, who is a professor at the University of Washington School of Medicine and a member of the Fred Hutchinson Cancer Research Center. Sacituzumab govitecan is an antibody-drug conjugate being investigated as a form of treatment for different types of solid cancers, including breast cancer. The medication contains an antibody that targets
Subscribe or to access all post and page content.